Initiation of immune checkpoint inhibitor therapy in winter is associated with improved overall survival in patients with advanced non-small cell lung cancer
Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein 1, programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4, have become a standard treatment resulting in improved outcomes in advanced non-small cell lung cancer (NSCLC); however, the influence of seasonal variations on trea...